Panavance Therapeutics Inc.

About

Panavance Therapeutics Inc. is a clinical-stage pharmaceutical company established in 2021 and based in Berwyn, PA. Our novel oncology therapeutic, GP-2250, has the potential to impact across diverse oncological disease states by targeting the primary source of cancer cell energy production with its unique and patent-pending mechanism of action. The company is currently enrolling patients in a Phase 1 pancreatic cancer trial in 5 US clinical sites.